Diamyd Medical AB (publ)

DMYD-B · Nasdaq Stockholm · Healthcare

1.02SEK −0.6%last day

Price as of 2 October 2026

The price over the past year, with dividends: −91.3%

Performance

1 month

−1.4%

1 year

−91.3%

3 years, per year

−50.0%

5 years, per year

−47.0%

Largest fall, 3 years

−95.0%

Below the peak now

−98.5%

Volatility, 1 year

108.2%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

0.6

Dividend yield

0.0%

Return on equity

−109.3%

Net margin

−2.5%

Market value

15 m USD

Quality, value and trend

Where Diamyd Medical stands against every Nordic stock today. 100 is best.

Quality59

Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.

Value46

The price measured against earnings, assets and cash flow. Better than 46% of Nordic stocks.

Trend9

The price development over the past year. Better than 9% of Nordic stocks.

Combined25

Quality, value and trend together. Better than 25% of Nordic stocks.

About Diamyd Medical

Diamyd Medical AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 44 employees.

Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with type 1 diabetes, type 2 diabetes, and LADA. It has a research and development collaboration agreement with Juvenile Diabetes Research Foundation to develop DIAGNODE-3 Phase 3 trial in type 1 diabetes.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis